CLOMIPHENE CITRATE tablet

Ország: Egyesült Államok

Nyelv: angol

Forrás: NLM (National Library of Medicine)

Vedd Meg Most

Termékjellemzők Termékjellemzők (SPC)
10-04-2014

Aktív összetevők:

CLOMIPHENE CITRATE (UNII: 1B8447E7YI) (CLOMIPHENE - UNII:1HRS458QU2)

Beszerezhető a:

Physicians Total Care, Inc.

INN (nemzetközi neve):

CLOMIPHENE CITRATE

Összetétel:

CLOMIPHENE CITRATE 50 mg

Az alkalmazás módja:

ORAL

Recept típusa:

PRESCRIPTION DRUG

Terápiás javallatok:

Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION

Termék összefoglaló:

Clomiphene citrate tablets, USP, 50 mg are round, off-white, debossed “Par 701” with bisect on one side and plain on the other. They are supplied in blisterpack dispensing bottles of 5 (NDC 54868-3059-0); blisterpack dispensing bottles of 10 (NDC 54868-3059-1); and bottles of 30 (NDC 54868-3059-2). Storage - Store at controlled room temperature 15°-30°C (59°-86°F). Protect from heat, light, and excessive humidity, and store in closed containers. Manufactured by: PAR PHARMACEUTICAL COMPANIES, INC. Spring Valley, N Y 10977 Revised: 03/2013 Distributed by: Physicians Total Care, Inc. Tulsa, OK     74146

Engedélyezési státusz:

Abbreviated New Drug Application

Termékjellemzők

                                CLOMIPHENE CITRATE - CLOMIPHENE CITRATE TABLET
PHYSICIANS TOTAL CARE, INC.
----------
DESCRIPTION
Clomiphene citrate tablets, USP is an orally administered,
nonsteroidal, ovulatory stimulant designated
chemically as 2-[p-(2chloro-1,2-diphenylvinyl)phenoxy] triethylamine
citrate (1:1). It has the molecular
formula of C
H CINO • C H O and a molecular weight of 598.10. It is represented
structurally as:
Clomiphene citrate is a white to pale yellow, essentially odorless,
crystalline powder. It is freely
soluble in methanol; soluble in ethanol; slightly soluble in acetone,
water, and chloroform; and insoluble
in ether.
Clomiphene citrate is a mixture of two geometric isomers [cis
(zuclomiphene) and trans (enclomiphene)]
containing between 30% and 50% of the cis-isomer.
Each off-white debossed tablet contains 50 mg clomiphene citrate USP.
The tablet also contains the
following inactive ingredients: corn starch, lactose monohydrate,
magnesium stearate, pregelatinized
corn starch, and sucrose.
CLINICAL PHARMACOLOGY
ACTION
Clomiphene citrate is a drug of considerable pharmacologic potency.
With careful selection and proper
management of the patient, clomiphene citrate has been demonstrated to
be a useful therapy for the
anovulatory patient desiring pregnancy.
Clomiphene citrate is capable of interacting with
estrogen-receptor-containing tissues, including the
hypothalamus, pituitary, ovary, endometrium, vagina, and cervix. It
may compete with estrogen for
estrogen-receptor-binding sites and may delay replenishment of
intracellular estrogen receptors.
Clomiphene citrate initiates a series of endocrine events culminating
in a preovulatory gonadotropin
surge and subsequent follicular rupture. The first endocrine event in
response to a course of
clomiphene therapy is an increase in the release of pituitary
gonadotropins. This initiates
steroidogenesis and folliculogenesis, resulting in growth of the
ovarian follicle and an increase in the
circulating level of estradiol. Following ovulation, plasma
progesterone and estradiol
                                
                                Olvassa el a teljes dokumentumot
                                
                            

A termékkel kapcsolatos riasztások keresése

Dokumentumelőzmények megtekintése